[Risk of fungal disease during systemic diseases].
Invasive fungal diseases are sparse but responsible for a high mortality. During systemic diseases, they are less common than bacterial infection but are probably underdiagnosed. Diagnosis of invasive fungal disease might be difficult: clinical signs may mimic systemic diseases, uninvasive diagnostic tools have not been evaluated in this situation and invasive exploration (histology) is rarely done. Guidelines for invasive fungal disease curative treatment are available but preventive strategies need to be evaluated in the population of patients with systemic diseases.
Lebeaux
David
D
Service des Maladies Infectieuses et Tropicales, Université Paris Descartes, Hôpital Necker Enfants Malades, Centre d'Infectiologie Necker-Pasteur, F-75743 Paris Cedex 15, France.
Lanternier
Fanny
F
Lefort
Agnès
A
Lecuit
Marc
M
Lortholary
Olivier
O
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001228:Aspergillosis / Q000453:epidemiology; D003047:Coccidioidomycosis / Q000453:epidemiology; D003453:Cryptococcosis / Q000453:epidemiology; D006660:Histoplasmosis / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D009145:Mushroom Poisoning / Q000150:complications / Q000188:drug therapy; D009181:Mycoses / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents